- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT01861080
Korean Registry of Target Organ Damages in Hypertension (KorHR)
Observational Study of Clinical Characteristics and Prognostic Factors of Korean Hypertensives
Studieöversikt
Status
Betingelser
Detaljerad beskrivning
Background: the exact prevalence of target organ damages in Korean hypertensives are unknown.
Study Objective: to investigate the prevalence of target organ damages in Korean patients with incident hypertension.
Study Design: prospective, multi-center and observational study
Study Populaton: approximately 5000 consecutive patients with incident hypertension, who visited outpatients clinics and agreed to participate in the registry
Primary outcome
Subclinical organ damages
- left ventricular hypertrophy on electrocardiogram or echocardiography
- increased intima media thickness of carotid artery (> 0.9 mm) or plaque
- increased pulse wave velocity (> 12 m/s)
- low estimated glomerular filtration rate (< 60 ml/min/1.73 m2) or creatinine clearance (<60 ml/min)
Established CV or renal disease
- cerebrovascular disease: ischemic stroke; cerebral stroke; transient ischemic attack
- Heart disease: myocardial infarction; angina; coronary revascularization; heart failure
- Renal disease: diabetic retinopathy; serum creatinine M > 133, W > 124 mmol/L; proteinuria > 300 mg/24 hr
- Peripheral artery disease
- Advanced retinopathy: hemorrhage or exudates, papilledema
Studietyp
Inskrivning (Förväntat)
Kontakter och platser
Studieorter
-
-
Gyeonggido
-
Hwaseong, Gyeonggido, Korea, Republiken av, 445-170
- Hallym University Dongtan Sacred Heart Hospital,
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Beskrivning
Inclusion Criteria:
- age≧30years
- primary incident hypertension
- singed informed consent
Exclusion Criteria:
- participated in other clinical trials
Studieplan
Hur är studien utformad?
Designdetaljer
Kohorter och interventioner
Grupp / Kohort |
---|
incident hypertensives
Inclusion Criteria:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
left ventricular hypertrophy
Tidsram: at enrollment
|
left ventricular hypertrophy on electrocardiogram or echocardiography Sokolow-Lyon > 38 mm; left ventricular mass index male >= 125 g/m2, female >=110 g/m2)
|
at enrollment
|
Intima media thickness of carotid artery
Tidsram: at enrollment
|
increased intima media thickness of carotid artery (> 0.9 mm) or presence of plaque
|
at enrollment
|
pulse wave velocity
Tidsram: at enrollment
|
increased pulse wave velocity (> 12 m/s)
|
at enrollment
|
kidney function
Tidsram: at enrollment
|
low estimated glomerular filtration rate (< 60 ml/min/1.73
m2) or creatinine clearance (< 60 ml/min)
|
at enrollment
|
cerebrovascular accident
Tidsram: at enrollment
|
ischemic stroke, cerebral hemorrhage, or transient ischemic attack confirmed by a neurologist
|
at enrollment
|
renal disease
Tidsram: at enrollment
|
serum creatinine male > 1.5 mg/dl, female > 1.4 mg/dl; proteinuria > 300 mg/24hr
|
at enrollment
|
peripheral artery disease
Tidsram: at enrollment
|
ankle to brachial blood pressure ratio < 0.9
|
at enrollment
|
retinopathy
Tidsram: at enrollment
|
retinal hemorrhage or exudate, papilledema confirmed by an ophthalmologist
|
at enrollment
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Hypertension
Tidsram: at enrollment
|
high blood pressure confirmed by ambulatory blood pressure monitoring (24hr average systolic blood pressure >=135 mm Hg, diastolic blood pressure >= 85 mm Hg
|
at enrollment
|
Dyslipidemia
Tidsram: at enrollment
|
total cholesterol 190 mg/dl or LDL > 115 mg/dl, HDL male < 40 mg/dl, female < 46 mg/dl or triglyceride > 150 mg/dl
|
at enrollment
|
abnormal fasting plasma glucose
Tidsram: at enrollment
|
abnormal fasting plasma glucose (102-125 mg/dl)
|
at enrollment
|
abdominal obesity
Tidsram: at enrollment
|
waist circumference male > 102 cm, female > 88 cm
|
at enrollment
|
diabetes mellitus
Tidsram: at enrollment
|
fasting plasma glucose >= 126 mg/dl; postload plasma glucose > 198 mg/dl
|
at enrollment
|
Andra resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
major cardiovascular events
Tidsram: after follow-up period of 36 months
|
death, stroke, myocardial infarction and heart failure(confirmed by a cardiologist)
|
after follow-up period of 36 months
|
Samarbetspartners och utredare
Sponsor
Utredare
- Huvudutredare: Kyu-Hyung Ryu, MD, PhD, Dongtan Sacred Heart Hospital, Hallym University
Publikationer och användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Förväntat)
Avslutad studie (Förväntat)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- 2012-005
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Hypertoni
-
Pfizer's Upjohn has merged with Mylan to form Viatris...Avslutad
-
NovartisAvslutad
-
NovartisAvslutadMETABOLISKT SYNDROM | HYPERTENSION | PRE-HYPERTENSIONFörenta staterna
-
Centre Chirurgical Marie LannelongueOkändKronisk trombo-embolisk pulmonell hypertension och pulmonell arteriell hypertensionFrankrike
-
NovartisAvslutadHYPERTENSION | HYPERKOLESTEROLEMIFörenta staterna
-
University Hospital, BonnRekryteringKardiomyopatier | Hypertoni, PortalTyskland
-
University Hospital, ToursAvslutadCirrhotic Portal HypertensionFrankrike
-
Assistance Publique - Hôpitaux de ParisAktiv, inte rekryterandeIntrahepatisk icke-cirrhotisk portalhypertoniFrankrike
-
Ain Shams UniversityAvslutad